Picture loading failed.

Anti-ANGPT2 therapeutic antibody (Pre-made Nesvacumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Nesvacumab is an experimental monoclonal antibody originally designed for the treatment of cancer. It targets the protein angiopoietin 2. As of May 2017, it is in Phase II clinical trials for the treatment of diabetic macular edema.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-373-1mg 1mg 3090
GMP-Bios-ab-373-10mg 10mg 21890
GMP-Bios-ab-373-100mg 100mg 148000
GMP-Bios-ab-373-xmg >100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-ANGPT2 therapeutic antibody (Pre-made Nesvacumab biosimilar,Whole mAb)
INN Name Nesvacumab
TargetANGPT2
FormatWhole mAb
DerivationHuman
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-I
Est. StatusDiscontinued
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2012
Year Recommended2013
CompaniesRegeneron Pharmaceuticals;Sanofi
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedSolid tumours
Development Techna